ABBV – AbbVie Inc.
Float Short %
0.87
Margin Of Safety %
-5
Put/Call OI Ratio
0.78
EPS Next Q Diff
0.36
EPS Last/This Y
9.57
EPS This/Next Y
2.26
Price
218.31
Target Price
219.44
Analyst Recom
1.9
Performance Q
13.47
Relative Volume
0.8
Beta
0.5
Ticker: ABBV
of 1
| Date | Symbol | Last | P/C OI | P/C Vol | Total OI |
|---|---|---|---|---|---|
| 2025-08-15 | ABBV | 206.71 | 0.66 | 0.42 | 338013 |
| 2025-08-18 | ABBV | 206.53 | 0.72 | 0.72 | 267065 |
| 2025-08-19 | ABBV | 206.28 | 0.74 | 5.43 | 280861 |
| 2025-08-20 | ABBV | 209.1 | 0.80 | 0.72 | 293995 |
| 2025-08-21 | ABBV | 209.98 | 0.80 | 0.25 | 297761 |
| 2025-08-22 | ABBV | 210.63 | 0.76 | 0.62 | 310375 |
| 2025-08-25 | ABBV | 207.49 | 0.78 | 0.76 | 302913 |
| 2025-08-26 | ABBV | 208.36 | 0.78 | 0.82 | 307848 |
| 2025-08-27 | ABBV | 208.12 | 0.79 | 0.57 | 310422 |
| 2025-08-28 | ABBV | 207.95 | 0.79 | 0.46 | 312437 |
| 2025-08-29 | ABBV | 210.53 | 0.79 | 0.49 | 313415 |
| 2025-09-02 | ABBV | 211.91 | 0.79 | 0.58 | 309609 |
| 2025-09-03 | ABBV | 211.86 | 0.79 | 0.92 | 312998 |
| 2025-09-04 | ABBV | 213.09 | 0.79 | 0.52 | 317264 |
| 2025-09-05 | ABBV | 212.5 | 0.79 | 0.90 | 319452 |
| 2025-09-08 | ABBV | 209.84 | 0.80 | 0.24 | 315750 |
| 2025-09-09 | ABBV | 210.41 | 0.76 | 0.16 | 328394 |
| 2025-09-10 | ABBV | 211.68 | 0.75 | 0.29 | 331871 |
| 2025-09-11 | ABBV | 220.22 | 0.75 | 0.39 | 334778 |
| 2025-09-12 | ABBV | 218.92 | 0.78 | 0.78 | 335301 |
| Date | Symbol | Last | P/C OI | P/C Vol | Total OI |
Current Page1 of 1
of 1
| Date | Ticker | Price | Current Quarter Growth Estimate | EBIT Estimation | Average EPS Estimate Current Year |
|---|---|---|---|---|---|
| 2025-08-15 | ABBV | 206.71 | 8.7 | 21720.7 | 11.97 |
| 2025-08-18 | ABBV | 206.52 | 9.0 | 21510.8 | 11.97 |
| 2025-08-19 | ABBV | 206.19 | 9.0 | 21487.0 | 11.97 |
| 2025-08-20 | ABBV | 209.08 | 9.0 | 21856.9 | 11.97 |
| 2025-08-21 | ABBV | 209.59 | 9.0 | 21247.6 | 11.97 |
| 2025-08-22 | ABBV | 210.62 | 9.0 | 21322.4 | 11.97 |
| 2025-08-25 | ABBV | 207.49 | 9.1 | 20858.2 | 11.97 |
| 2025-08-26 | ABBV | 208.36 | 9.1 | 21289.4 | 11.97 |
| 2025-08-27 | ABBV | 208.05 | 9.1 | 21165.1 | 11.97 |
| 2025-08-28 | ABBV | 207.90 | 9.1 | 21181.7 | 11.97 |
| 2025-08-29 | ABBV | 210.23 | 9.1 | 21455.2 | 11.97 |
| 2025-09-02 | ABBV | 211.88 | 9.1 | 21361.2 | 11.97 |
| 2025-09-03 | ABBV | 211.87 | 9.1 | 25277.7 | 11.97 |
| 2025-09-04 | ABBV | 213.03 | 9.1 | 25430.7 | 11.97 |
| 2025-09-05 | ABBV | 212.56 | 9.1 | 25609.5 | 11.97 |
| 2025-09-08 | ABBV | 209.79 | 9.1 | 25314.1 | 11.97 |
| 2025-09-09 | ABBV | 210.41 | 9.1 | 25744.8 | 11.97 |
| 2025-09-10 | ABBV | 211.67 | 9.1 | 25825.4 | 11.97 |
| 2025-09-11 | ABBV | 220.22 | 9.1 | 26757.8 | 11.97 |
| 2025-09-12 | ABBV | 218.31 | 9.1 | 25431.8 | 11.97 |
| Date | Ticker | Price | Current Quarter Growth Estimate | EBIT Estimation | Average EPS Estimate Current Year |
Current Page1 of 1
of 1
| Date | Ticker | Insider Transactions | Institutional Transactions | Float Short |
|---|---|---|---|---|
| 2025-08-15 | ABBV | -11.92 | 1.27 | 0.86 |
| 2025-08-18 | ABBV | -11.92 | 1.11 | 0.86 |
| 2025-08-19 | ABBV | -15.92 | 1.11 | 0.86 |
| 2025-08-20 | ABBV | -15.92 | 1.11 | 0.86 |
| 2025-08-21 | ABBV | -15.92 | 1.11 | 0.86 |
| 2025-08-22 | ABBV | -15.92 | 1.11 | 0.86 |
| 2025-08-25 | ABBV | -14.47 | 0.15 | 0.86 |
| 2025-08-26 | ABBV | -14.47 | 0.15 | 0.86 |
| 2025-08-27 | ABBV | -14.47 | 0.15 | 0.96 |
| 2025-08-28 | ABBV | -14.47 | 0.15 | 0.96 |
| 2025-08-29 | ABBV | -14.47 | 0.15 | 0.96 |
| 2025-09-02 | ABBV | -12.59 | 0.20 | 0.96 |
| 2025-09-03 | ABBV | -12.59 | 0.20 | 0.96 |
| 2025-09-04 | ABBV | -12.59 | 0.20 | 0.96 |
| 2025-09-05 | ABBV | -6.37 | 0.20 | 0.96 |
| 2025-09-08 | ABBV | -6.37 | 0.11 | 0.96 |
| 2025-09-09 | ABBV | -6.37 | 0.11 | 0.96 |
| 2025-09-10 | ABBV | -6.37 | 0.11 | 0.96 |
| 2025-09-11 | ABBV | -6.37 | 0.11 | 0.87 |
| 2025-09-12 | ABBV | -6.37 | 0.11 | 0.87 |
| Date | Ticker | Insider Transactions | Institutional Transactions | Float Short |
Current Page1 of 1
Last Quarter Act. EPS
2.97
Avg. EPS Est. Current Quarter
3.27
Avg. EPS Est. Next Quarter
3.33
Insider Transactions
-6.37
Institutional Transactions
0.11
Beta
0.5
Average Sales Estimate Current Quarter
15583
Average Sales Estimate Next Quarter
16329
Fair Value
207.19
Quality Score
67
Growth Score
82
Sentiment Score
74
Actual DrawDown %
0.2
Max Drawdown 5-Year %
-21.9
Target Price
219.44
P/E
103.91
Forward P/E
15.33
PEG
6.57
P/S
6.61
P/B
P/Free Cash Flow
21.15
EPS
2.1
Average EPS Est. Cur. Y
11.97
EPS Next Y. (Est.)
14.23
Target Price Estimates Raised
Target Price Estimates Lowered
Profit Margin
6.38
Relative Volume
0.8
Return on Equity vs Sector %
-2059.3
Return on Equity vs Industry %
-2067.9
EPS 1 7Days Diff
EPS 1 30Days Diff
EBIT Estimation
25431.8
AbbVie Inc.Sector: Healthcare
Industry: Drug Manufacturers - General
Employees: 55000
AbbVie Inc., a research-based biopharmaceutical company, engages in the research and development, manufacture, commercialization, and sale of medicines and therapies worldwide. The company offers Humira, an injection for autoimmune and intestinal Behçet's diseases, generalized pustular psoriasis, and pyoderma gangrenosum; Skyrizi to treat autoimmune diseases, erythrodermic psoriasis, generalized pustular psoriasis, and palmoplantar pustulosis; Rinvoq to treat inflammatory diseases; Imbruvica for the treatment of adult patients with blood cancers; Venclexta/Venclyxto to treat blood cancers; Elahere to treat various cancer; and Epkinly to treat lymphoma. It also provides facial injectables, plastics and regenerative medicine, body contouring, and skincare products; botox therapeutic to treat neurologic diseases; Vraylar to treat schizophrenia, bipolar disorder, and depressive disorder; Duopa and Duodopa to treat Parkinson's disease; Ubrelvy to treat migraine; and Qulipta for episodic and chronic migraine, as well as other neuroscience products. In addition, the company offers Ozurdex for eye diseases; Lumigan/Ganfort and Alphagan/Combigan for the reduction of elevated intraocular pressure in patients with open angle glaucoma or ocular hypertension; Restasis to increase tear production; and other eye care products. Further, it provides Mavyret/Maviret to treat chronic hepatitis C virus genotype 1-6 infection; Creon, a pancreatic enzyme therapy; and Linzess/Constella to treat irritable bowel syndrome with constipation and chronic idiopathic constipation. The company was incorporated in 2012 and is headquartered in North Chicago, Illinois.
stock quote shares ABBV – AbbVie Inc. Stock Price stock today
news today ABBV – AbbVie Inc. stock forecast ,stock prediction 2023 2024 2025
marketwatch ABBV – AbbVie Inc. yahoo finance google finance
stock history ABBV – AbbVie Inc. invest stock market
stock prices ABBV premarket after hours
ticker ABBV fair value insiders trading